No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

In the literature there is no consensus on the correlation between early systemic intervention and better treatment response in psoriasis. Here we present data on the impact of disease duration (<5 years, 5‐<10 years, and ≥10 years) on response to tildrakizumab treatment among patients with mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Griss, Johannes, Ratzinger, Gudrun, Maul, Julia‐Tatjana, Weger, Wolfgang, Thaçi, Diamant, Carrascosa, José Manuel, Jonak, Constanze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549803/
https://www.ncbi.nlm.nih.gov/pubmed/37799374
http://dx.doi.org/10.1002/ski2.263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549803/
https://www.ncbi.nlm.nih.gov/pubmed/37799374
http://dx.doi.org/10.1002/ski2.263

Ejemplares similares